TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRxBusiness Wire • 03/07/22
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022Business Wire • 03/01/22
TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing LimitsBenzinga • 12/13/21
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®Business Wire • 12/10/21
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry DateBusiness Wire • 12/08/21
TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q3 2021 Earnings Conference Call - Earnings Call TranscriptSeeking Alpha • 11/11/21
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive OfficerBusiness Wire • 11/11/21
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 11/04/21
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business OfficerBusiness Wire • 10/15/21
Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*Business Wire • 09/21/21
Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness MonthBusiness Wire • 09/02/21